Want to see EMBC full AI Analyst Report?
EMBC Stock Chart & Stats
$3.29
$0.18(5.47%)
At close: 4:00 PM EDT
$3.29
$0.18(5.47%)
Day’s Range― - ―
52-Week Range$2.77 - $15.55
Previous CloseN/A
Volume395.36K
Average Volume (3M)2.04M
Market Cap
$215.95M
Enterprise Value$1.70K
Total Cash (Recent Filing)$214.70M
Total Debt (Recent Filing)$1.49B
Price to Earnings (P/E)1.9
Beta0.65
Next Earnings
Dec 01, 2026EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend Yield12.64%
Share Statistics
EPS (TTM)1.49
Shares Outstanding59,327,680
10 Day Avg. Volume1,215,714
30 Day Avg. Volume2,041,617
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)-1.26
Price to Sales (P/S)0.76
P/FCF Ratio4.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$3.00Price Target Upside-8.81% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)1.59
Revenue Forecast (FY)$1.02B
Bulls Say, Bears Say
Bulls Say
Cash GenerationSustained positive operating and free cash flow shows the core business converts earnings into cash. This durable cash generation supports ongoing debt repayment targets, funds integration of acquisitions, and finances product development or restructuring without immediate reliance on external financing.
High Product MarginsStrong gross margins reflect scalable manufacturing of recurring consumables (pen needles, syringes). Durable margin advantage on core products can sustain profitability through cycle swings, enabling reinvestment in R&D, commercial expansion, and margin recovery if volumes stabilize.
Strategic Diversification (Owen Mumford + GLP‑1 B2B)The OM acquisition and expanding GLP‑1 B2B partnerships materially broaden the product portfolio and addressable markets, reducing reliance on pen‑needle volumes. These structural moves create pharma-channel exposure, diversified revenue streams, and medium‑term growth avenues that persist beyond short‑term cyclical weakness.
Bears Say
Stressed Balance SheetPersistently negative equity and high absolute debt create structural financial vulnerability. This limits capital flexibility, increases refinancing and covenant sensitivity, and raises funding cost risk over months if operating cash flow softens, constraining strategic options during recovery.
U.S. Share Loss & Product DeclinesLarge, concentrated U.S. share loss—especially in pen needles which drive volumes—signals durable competitive and channel shifts. When a single-customer share loss and channel affordability changes drive volume declines, recovery can be slow and may permanently reduce scale economics in the U.S. market.
Material Guidance & Margin CutsSignificant downward revisions to revenue, margins and free cash flow reflect weaker underlying demand and reduced operating leverage. Over 2–6 months this compresses capacity to accelerate growth, slows debt paydown targets, and reduces discretionary investment in product launches or commercial recovery initiatives.
Embecta Corporation News
EMBC FAQ
What was Embecta Corporation’s price range in the past 12 months?
Embecta Corporation lowest stock price was $2.77 and its highest was $15.55 in the past 12 months.
What is Embecta Corporation’s market cap?
Embecta Corporation’s market cap is $215.95M.
When is Embecta Corporation’s upcoming earnings report date?
Embecta Corporation’s upcoming earnings report date is Dec 01, 2026 which is in 116 days.
How were Embecta Corporation’s earnings last quarter?
Embecta Corporation released its earnings results on Aug 07, 2026. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.266 by $0.294.
Is Embecta Corporation overvalued?
According to Wall Street analysts Embecta Corporation’s price is currently Overvalued.
Does Embecta Corporation pay dividends?
Embecta Corporation pays a Quarterly dividend of $0.01 which represents an annual dividend yield of 12.64%. See more information on Embecta Corporation dividends here
What is Embecta Corporation’s EPS estimate?
Embecta Corporation’s EPS estimate is 0.33.
How many shares outstanding does Embecta Corporation have?
Embecta Corporation has 59,327,680 shares outstanding.
What happened to Embecta Corporation’s price movement after its last earnings report?
Embecta Corporation reported an EPS of $0.56 in its last earnings report, beating expectations of $0.266. Following the earnings report the stock price went down -57.835%.
Which hedge fund is a major shareholder of Embecta Corporation?
Currently, no hedge funds are holding shares in EMBC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Embecta Corporation Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$3.00 (-8.81% Downside)
$3.00 (-8.81% Downside)
Blogger Sentiment
Neutral
EMBC Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 825.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.5%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.88%
12-Months-Change
Fundamentals
Return on Equity
12.64%
Trailing 12-Months
Asset Growth
-8.11%
Trailing 12-Months
Company Description
Embecta Corporation
Embecta Corp. is a medical technology enterprise devoted to enhancing the quality of life and health outcomes for individuals living with diabetes. Its comprehensive product portfolio includes essential tools such as pen needles, syringes, and advanced safety devices. Additionally, the company provides innovative digital applications designed to support patients in effectively managing their condition. Embecta distributes its offerings primarily through a network of wholesalers and distributors, reaching markets both domestically within the United States and across the globe. Established in 1924, Embecta's headquarters are located in Parsippany, New Jersey. The company transitioned to an independent entity from Becton, Dickinson and Company on April 1, 2022.
EMBC Company Deck
EMBC Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Negative
The call presents meaningful strategic progress (Owen Mumford acquisition, GLP‑1 B2B traction, brand transition progress, debt repayment and a share buyback authorization) but was dominated by substantial near‑term operational and financial setbacks: large revenue declines (especially in the U.S. and pen needles), sharp margin and EPS guide cuts, a GAAP net loss in the quarter, and material reductions in free cash flow guidance. Management has initiated cost/organization reviews and highlighted actions underway, but the magnitude and persistence of the U.S. share loss and market volume softness create significant short‑term headwinds.View all EMBC earnings summariesEMBC Stock 12 Month Forecast
Average Price Target
$3.00
▼(-8.81% Downside)
Technical Analysis
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
Collegium Pharmaceutical
―
Organogenesis Holdings
―
Ownership Overview
3.24% Insiders
29.04% Mutual Funds
1.92% Other Institutional Investors
52.12% Public Companies and
Individual Investors